Mark Cornfeld

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

Frits van Rhee, Luis Fayad, Peter M. Voorhees et al. · Journal of Clinical Oncology · 2010 · 240 citations

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Karim Fizazi, Johann S. de Bono, Aude Fléchon et al. · European Journal of Cancer · 2011 · 192 citations

Urology, Anti-il-6 Monoclonal Antibody, Medicine +8

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Anthony W. Tolcher, Amita Patnaik, Kyriakos P. Papadopoulos et al. · Cancer Chemotherapy and Pharmacology · 2014 · 155 citations

Oncology, Medicine, Multiple Myeloma +8

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Juneko E. Grilley‐Olson, Philippe L. Bédard, Angelica Fasolo et al. · Investigational New Drugs · 2016 · 80 citations · Full text

Medicine, Metronomic Therapy, Pharmacology +7

Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Sally A. Hunsucker, Valeria Magarotto, Deborah J. Kuhn et al. · British Journal of Haematology · 2011 · 78 citations · Full text